Celltrion, Inc.
Financials
Valuation Metrics
Celltrion, Inc.'s Market Cap is ₩43.2T. At end of 2025 it was ₩40.1T. Ranked #17 of 2,436 in KR market (top 0.7%), #17 of 787 on KOSPI (top 2%), #2 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.9%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 43.21T KRW | KR#17/2,436 Sec#2/234 |
| Revenue | 4.47T KRW | KR#136/2,436 Sec#2/234 |
| Net Income | 1.27T KRW | KR#38/2,436 Sec#2/234 |
| Total Assets | 23.16T KRW | KR#68/2,436 Sec#1/234 |
| Net Assets | 17.81T KRW | KR#33/2,436 Sec#1/234 |
| Employees | 2,901 | KR#106/2,436 Sec#2/234 |
| Value | ||
| P/E | 33.94x | KR#1,286/2,436 Sec#81/234 |
| P/B | 2.43x | KR#2,023/2,436 Sec#154/234 |
| PEG | 0.15x | KR#463/2,436 Sec#25/234 |
| P/S | 9.68x | KR#2,261/2,436 Sec#160/234 |
| EV/EBITDA | 34.05x | KR#1,231/2,436 Sec#84/234 |
| FCF Yield | 1.50% | KR#1,109/2,436 Sec#77/234 |
| Profitability | ||
| ROE | 7.15% | KR#774/2,436 Sec#54/234 |
| ROA | 5.50% | KR#595/2,436 Sec#44/234 |
| Op. Margin | 30.03% | KR#57/2,436 Sec#13/234 |
| Revenue Growth | 36.00% | KR#403/2,436 Sec#36/234 |
| Earnings Growth | 222.93% | KR#229/2,436 Sec#15/234 |
| Financial Health | ||
| Debt Ratio | 29.99% | KR#94/2,436 Sec#11/234 |
| Total Debt | 3.74T KRW | KR#87/2,436 Sec#1/234 |
| FCF | 646.05B KRW | KR#47/2,436 Sec#2/234 |
| Cash | 1.29T KRW | KR#73/2,436 Sec#1/234 |
| Current Ratio | 1.39x | KR#1,401/2,436 Sec#149/234 |
| Net Debt/EBITDA | 1.83x | KR#877/2,436 Sec#63/234 |
| Dividend | ||
| Div. Yield | 0.39% | KR#1,305/2,436 Sec#86/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 12.09% | KR#502/2,436 Sec#42/234 |
| 1M Return | 1.20% | KR#762/2,436 Sec#68/234 |
| From 52W High | -22.34% | KR#217/2,436 Sec#11/234 |
| 1Y MDD | -32.70% | KR#280/2,436 Sec#18/234 |
| Trading | ||
| Volume | 521,153 shares | KR#265/2,436 Sec#26/234 |
| Foreign Own. | 24.76% | KR#164/2,436 Sec#6/234 |
| Per Share | ||
| EPS | 5,226 KRW | KR#167/2,436 Sec#11/234 |
| BPS | 76,797 KRW | KR#170/2,436 Sec#10/234 |
Company Info
Celltrion, established in 1991, completed its KOSDAQ listing in 2005 and transferred to the Securities Market in 2018, building a unified corporate structure through the absorption merger of Celltrion Healthcare in 2023. It develops, produces, and sells antibody drugs using biotechnology and animal cell mass culture technology, possessing an 11-product portfolio. The company is strengthening its next-generation antibody drug pipeline through alliances and investments with global biotech companies. Celltrion is headquartered in Yeonsu-gu, Incheon Metropolitan City.